Stock Ticker

  • Loading stock data...

GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets

On Wednesday, GlaxoSmithKline plc (ADR) (NYSE:GSK) divulged its growth goals. This is an endeavor to persuade investors that concentrating on consumer health and vaccines would bring back long-term growth.

It also discarded plans to float its HIV drug business ViiV Healthcare pointing to its strong outlook. Further, it pledged to disburse a regular dividend of 80 pence a share over the next three years.

Chief Executive Andrew Witty is facing a lot of pressure to demonstrate to investors that a $20 billion asset swap with Novartis AG (ADR) (NYSE:NVS) can propel GSK’s ascent. This is subsequent to a damaging decline in lung drug sales and a big corruption scandal in China.

Britain’s largest drugmaker stated that it anticipated group sales to grow by a low-to-mid single-digit percentage rate yearly till 2020. Its pharmaceuticals, vaccines and consumer health enterprises would experience yearly sales growth by low single digits, mid-to-high digits, and mid-single digits respectively.

In an attempt to safeguard its dividend, GSK scaled down plans to give 4 billion pounds of cash coming from the Novartis transaction. Rather, it will disburse 1 billion pounds as a special dividend.

GSK traded its cancer drugs portfolio for Novartis’s vaccines.Simultaneously, it entered into a joint venture with the Swiss firm to enhance its consumer health enterprise.

This move decreases GSK’s dependence on risky drug development and boosts its exposure to more stable consumer and vaccines operations. The latter possesses long lasting products and lower margins when it comes to consumer health.

Certain investors are very doubtful of the logic of decreasing exposure to prescription drugs development at a juncture when industry competitors are leveraging the latest science to create a host of potential novel blockbusters.

However Witty, who is managing the largest shake-up since GlaxoSmithKline plc (ADR) (NYSE:GSK) was created through a merger fifteen years back, is gambling on diversification and views its enlarged consumer health division as a potent player in an expanding market.

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email ([email protected]) or his Google+ page (https://plus.google.com/u/0/116608759701551457422).

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts